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Abstract  
Oculopharyngeal muscular dystrophy (OPMD) is a rare late onset genetic disease leading to ptosis, 
dysphagia, and proximal limb muscles at later stages. A short abnormal (GCN) triplet expansion 
in the polyA-binding protein nuclear 1 (PABPN1) gene leads to PABPN1-containing aggregates in 
the muscles of OPMD patients. Here we demonstrate that treating mice with guanabenz acetate 
(GA), an FDA-approved antihypertensive drug, reduces the size and number of nuclear aggregates, 
improves muscle force, protects myofibers from the pathology-derived turnover and decreases 
fibrosis. GA targets various cell processes, including the unfolded protein response (UPR), which 
acts to attenuate endoplasmic reticulum (ER) stress. We demonstrate that GA increases both the 
phosphorylation of the eukaryotic translation initiator factor 2α subunit (eIF2α) and the splicing of 
Xbp1, key components of the UPR. Altogether these data show that modulation of protein folding 
regulation is beneficial for OPMD and promote the further development of GA or its derivatives 
for treatment of OPMD in humans. Furthermore, they support the recent evidences that treating ER 
stress could be therapeutically relevant in other more common proteinopathies.  
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Introduction  
Oculopharyngeal muscular dystrophy (OPMD) is a late onset rare autosomal dominant muscular 
dystrophy. It affects 1:100000 people in Europe but it is more common in population groups such 
as the Bukharan Jews (1/600) and in Quebec (1/1000) likely due to founder effects (1, 2). OPMD 
is characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia) and 
proximal limb weakness. It is caused by a mutation in the poly(A) binding protein nuclear 1 
(PABPN1) gene that introduces an abnormal expansion of alanine-encoding (GCN)n trinucleotide 
repeat in the coding region of exon 1 with 11-18 repeats leading to a mutant protein with an 
expanded number of alanines (expPABPN1, with 11-18 alanines instead of the normal 10) in the 
N terminal domain (3). PABPN1 is involved in several steps of mRNA and non-coding RNA 
biogenesis: PABPN1 controls mRNA poly(A) tail length (4, 5) and regulates the use of alternative 
polyadenylation (APA) sites (6, 7) with a direct effect on mRNA levels and stability. It is involved 
in splicing regulation (8, 9) and in the long non-coding RNA (lncRNA) (10) and small nucleolar 
RNA (snoRNA) processing (11). It also has an important role in poly(A)-mediated RNA decay or 
export from the nucleus (4) as well as in RNA hyperadenylation (12). Finally PABPN1 has been 
shown to be required for paraspeckle formation as well as for RNA editing (13). 
PABPN1 expression level varies across mouse and human tissues, and is exceptionally low in 
skeletal muscle (14). Mutated expPABPN1 is prone to form intranuclear aggregates but only in 
skeletal muscle (15, 16). To date the exact consequence of the presence of these aggregates in 
muscle still remains poorly understood but recent studies have suggested that expPABPN1 
aggregates that also sequesters wild-type PABPN1 in heterozygous patients could itself contribute 
to phenotypes associated with OPMD by a loss of function mechanism (13, 14, 17–19). This 
pathological function of PABPN1 aggregates is supported by the fact that higher frequency of 
aggregates is observed in severe homozygous patients (20). In addition, reducing PABPN1 
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aggregation by supplementing drugs such as trehalose or other supposed chaperones has 
consistently demonstrated enhanced cell survival in cell models of OPMD (21–23) and improved 
muscle weakness in both mouse and Drosophila models (2, 24, 25). Apoptosis and deregulation of 
the ubiquitin-proteasome system have also been proposed as potential downstream pathological 
events triggered by the aggregates (26, 27).  
There is currently no cure for OPMD and one of the only option for patients is the surgical 
cricopharyngeal myotomy to improve swallowing and surgical treatment of ptosis. Some 
innovative therapies are under development, including a phase I/IIa cell therapy trial involving 
autologous myoblast transplantation that has shown improvement in the swallowing capacity of 
OPMD patients with a cell dose effect (28). Several studies have shown promising results in animal 
models of the disease, mainly in Drosophila and in the A17 mouse model, where expPABPN1 is 
overexpressed under control of human skeletal muscle actin promoter (HSA1). A gene therapy 
approach tested in A17 mice showed a strong recovery from the disease (18). As mentioned above, 
anti-aggregation pharmacological strategies have shown positive results both in vitro and in vivo 
in the same A17 mouse model of OPMD (2, 21, 25, 27) and intravenous injection of trehalose is 
currently being used in a phase II clinical trial (29). Guanabenz acetate (GA), an FDA-approved 
antihypertensive drug agonist of α2-adrenergic receptors (30), was recently identified to display 
anti-prion activity through the inhibition of the protein folding activity (PFAR) mediated by the 
domain V of the large ribosomal RNA, which is a component of the large subunit of the ribosome 
(31, 32). GA was shown to be effective in the Drosophila model of OPMD when provided as oral 
treatment in the food, where it decreased muscle degeneration and reduced the size of aggregates 
(24). Deletions of the ribosomal DNA locus (encoding rRNAs mediating PFAR) was also shown 
to reduce OPMD phenotypes and act synergistically with sub-effective doses of 6-
aminophenanthridine, a PFAR inhibitor like GA (24), suggesting a mechanism involving the PFAR 
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(33, 34). Furthermore, GA has been shown to play a beneficial role in models of neurological 
diseases (e.g. Amyotrophic lateral sclerosis) by acting on the unfolded protein response (UPR). It 
has been proposed that GA could decrease protein burden in the endoplasmic reticulum (ER) and 
so increase the efficiency of ER chaperones by prolonging protein translation attenuation during 
ER stress (35, 36). ER stress condition activates the UPR through different pathways mediated by 
Grp78 (also called BiP, immunoglobulin-heavy-chain binding protein): first the dissociation of 
Grp78 from the protein kinase RNA (PRK)-like ER kinase (PERK) activates PERK that 
phosphorylates the α-subunit of eukaryotic translation initiation factor-2 (eIF2α). The 
phosphorylation of eIF2α attenuates the Cap-dependent protein translation and induces the 
translation of protein stress responses such as activating transcription factor 4 (ATF4) or protein 
phosphatase 1 regulatory subunit 15A (PPP1R15A). This latter has a crucial role in terminating the 
UPR pathway by binding to the catalytic subunit of protein phosphatase 1 holoenzyme (PP1c) and 
dephosphorylating eIF2α. The second branch of the UPR is initiated by the dissociation of Grp78 
from inositol requiring protein 1α (IRE-1α), which induces a non-canonical splicing of X-box 
binding protein 1 (XBP1) mRNA producing the active transcription factor XBP1s that in turn 
triggers the expression of several genes involved in protein folding. The third pathway is operated 
by the activating transcription factor 6 (ATF6), a receptor that under ER stress and its dissociation 
to Grp78 is translocated to the Golgi where it is cleaved to produce a fragment which then acts as 
a transcription factor to promote expression of XBP1 mRNA and other proteins involved in protein 
folding. It has been proposed that GA binds to PPP1R15A, thus preventing its binding to PP1c (37, 
38) and prolonging eIF2α phosphorylation with the effect of reducing the accumulation of 
misfolded proteins in the ER (37, 39), but these data are controversial (40, 41). 
Here we show that GA supplementation tested in the same dose range used for the marketed 
hypertensive GA-based drug Wytensin, significantly reduces the number of aggregates, decreases 
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fibrotic collagen deposition and pathological muscle turnover and improves muscle strength in the 
A17 mouse model of OPMD. As expPABPN1 expression in skeletal muscles induces the 
expression of ER stress markers, we studied the mechanism underlying the beneficial effects of 
GA in muscle cells and found that both Ire1α- and PERK-dependent branches of the UPR are 
affected by GA administration. Altogether, these results identify GA as a positive molecule for 
OPMD in the mouse model; they also suggest that ER stress plays a role in OPMD and that the 
modulation of UPR in response to ER stress has therapeutic potential to attenuate PABPN1 
aggregate toxicity. 
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Results 
 
Guanabenz effectively reduces PABPN1 aggregates in OPMD muscle cells  
GA has been shown to reduce the size of aggregates in a Drosophila model of OPMD (24). We 
first tested GA in the OPMD Ala17 muscle cell model. When differentiated, this myogenic cellular 
model expresses PABPN1-Ala17, resulting in the formation of a large number of nuclear 
aggregates (42, 43). GA was added to the cells at day 2 of differentiation and maintained in the 
medium for 72 additional hours. In these conditions, treatment with 10 µM of GA led to a 
significant reduction in the number and size of PABPN1-Ala17 aggregates (Figure 1a-d), without 
altering cell differentiation (Figure 1a and Supplementary figure 1a-d). At lower GA 
concentrations (ranging from 0.1 to 1 µM), we observed a dose-dependent reduction in the size of 
PABPN1-Ala17 aggregates but no effect on their number (Supplementary figure 2a-c).  
 
GA treatment induces a favorable change in stress response in Ala17 cells 
GA is known to affect the UPR in response to cellular ER stress (35–37, 44) by prolonging the 
phosphorylation of the α subunit of eukaryotic translation initiation factor 2 on Ser51 (P-eIF2α), a 
key component of the PERK branch of UPR, to slow down protein translation, decrease the ER 
protein accumulation in the ER and so leaving more time for the ER chaperones to correctly fold 
newly synthetized proteins (37). While no effect was observed in GA-treated versus non-treated 
control cells, a strong increase in phosphorylated eIF2α (P-eIF2α) was observed in GA-treated 
Ala17 cells (Figure 2a-b) compared to non-treated Ala17 cells. This effect was also observed at 
lower doses where phosphorylation was activated for all doses ranging from 10 to 0.05M of GA 
(Supplementary figure 2d-e). Significant changes in the expression of the same UPR-related 
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genes were observed in Ala17 treated cells in which Grp78, Grp94, Ddit3, Atf4 and Dnajc3 RNA 
levels were upregulated 24 hours after treatment compared to non-treated cells, while these levels 
were unchanged in control treated cells (Figure 2c). At 72 hours after treatment, levels of UPR 
related genes were back to normal in Ala17 treated cells (data not shown). As Grp78 also activates 
the IRE1α branch of the UPR, we evaluated if Xbp1 splicing was affected by GA supplementation. 
A strong increase in the spliced form of Xbp1 (Xbp1s) was detected in GA-treated Ala17 cells 
(Figure 2d) while no effect was observed on GA-treated control cells. The fact that control cells 
are not perturbed by GA administration indicates that GA itself does not induce UPR and is 
consistent with OPMD cells being challenged by ER stress. Whereas in the animal the expression 
of the mutated form of PABPN1 induces the UPR by itself, in Ala17 cells GA is needed to reveal 
UPR activation.  
Overall these data show that GA treatment in OPMD cells induces a favorable change in stress 
response, mediated by increased phosphorylation of eIF2α and Xbp1 splicing activation, which 
induces UPR-related proteins upregulation. Furthermore, GA treatment only modulates UPR in 
cells affected by ER stress. 
 
ER stress is detected in skeletal muscle of A17 mice  
GA is known to affect the UPR in response to cellular ER stress. No data are available on the ER 
stress condition and the relative unfolded protein response in muscles of the A17 mouse model of 
OPMD. Upon ER stress, it has been shown that the lumen of the ER is enlarged (45, 46). Using 
electron microscopy, we analyzed the skeletal muscle of A17 mice and observed that the muscle 
ER (sarcoplasmic reticulum, SR) was abnormally expanded in a number of glycolytic fibers 
compared to WT mice suggesting that this cellular organelle is indeed under stress (Figure 3a). In 
addition, analysis of gene expression profiles of A17 skeletal muscles compared to those of wild-
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type (WT) mice confirmed that the expression of ER genes (GO term: Endoplasmic reticulum 
subcompartment) is affected in OPMD mice (Figure 3b). This was further confirmed by qPCR 
analysis on A17 muscle cDNAs for several crucial UPR-related genes: the chaperones glucose-
regulated proteins 78 and 94 (Grp78, Grp94), the DNA damage-inducible transcript 3 Ddit3 (also 
named Chop), the activating transcription factor 4 (Atf4; downstream of PERK branch) and the 
DnaJ homolog subfamily C member 3 (Dnajc3; downstream of ATF6 branch) (Figure 3c). Xbp1 
splicing level remained unchanged in A17 mouse (figure 3c). These data confirm that expPABPN1 
expression in skeletal muscles induces the expression of ER stress markers, indicating that the A17 
mouse is a relevant OPMD model to evaluate the effect of GA on ER stress and its therapeutic 
potential in vivo.  
 
Treatment with GA in the A17 OPMD mouse model efficiently improves muscle strength, 
decreases pathological aggregates accumulation, myofiber turn-over, and fibrosis 
To test the effect of GA administration in the OPMD mouse model, 10-12 week old A17 mice were 
injected intraperitoneally (i.p.) with 4 mg/kg of GA (n=6) or with saline (n=6) three times per week 
(for a final dose of 12 mg/kg/week of GA) for 13 weeks. We chose this dose because it is in the 
range of the dose of drug used for the marketed GA-based Wytensin to treat hypertension in 
humans (47). Age-matched WT mice (FvB) (n=6) were also injected with saline as controls. At the 
end of the experiment, all mice gained a similar bodyweight irrespective of the treatment (data not 
shown). As GA has been shown to induce dizziness, weakness and sedation as possible side-effects 
(48), locomotor behavior of mice was examined by open field behavioral monitoring both after the 
first and before the last drug administration in the 13-week long study (Supplementary Table S2 
and Figure 4). After the first injection of GA (or saline in control mice), behavior of mice was 
monitored for 60 minutes and several parameters describing the animal activity were recorded. 
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This analysis showed that mice treated with GA were less active than mice injected with saline 
soon after GA administration (One-way ANOVA test, Supplementary figure 3a). However, the 
same analysis performed in mice just before the last injection of the study (with mice that were not 
under the effect of the drug at the time of the analysis) indicated that animals chronically treated 
with GA for 13 weeks are as active as mice injected with saline (One-way ANOVA test 
Supplementary figure 3b) suggesting no detrimental effect of a prolonged treatment with GA in 
locomotor activity of these mice. Before harvesting the samples from the treated mice, the forelimb 
force was analyzed by grip strength analysis. A17 mice have weaker forelimbs strength than FvB 
WT mice (25, 49). The treatment with GA significantly increased the muscle strength of treated 
A17 mice compared to saline injected A17 mice (Figure 4b). In a control pilot experiment we 
verified that GA had no effect on FvB WT mice (supplementary figure 4). To assess more 
precisely the muscle strength, TA muscles of saline and GA-treated mice were then analyzed by in 
situ electrophysiology force measurement. Muscles were stimulated with 9 consecutive trains of 
impulses from 10 to 180 Hz and the muscle strength provided after each train of stimulation was 
measured. GA treatment significantly increased the absolute maximal tetanic force generated by 
the muscles of A17 mice (Figure 4c). Normalization of the maximal tetanic force with the cross-
sectional area of the muscles provides a measure called maximal specific force, which is an 
indication of the muscle strength per unit of the muscle. Administration of GA to A17 mice 
significantly increased the maximal specific force and normalized the muscle strength to the WT 
level (Figure 4d-e). No difference in muscle weight was observed for tibialis anterior (TA), 
extensor digitorum longus (EDL), soleus (Sol) or gastrocnemius (Gast) (Supplementary figure 5). 
As GA is expected to reduce the amount of aggregates, muscles were analyzed for the presence of 
PABPN1 aggregates. The treatment with GA significantly reduced both the percentage of nuclei 
containing aggregates (one-way ANOVA test, from ~31% to ~22% of nuclei) and the size of 
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aggregates in TA skeletal muscles of A17 mice (Figure 5a-c), while the total level of PABPN1 
protein was unchanged (Figure 5d-e). Interestingly the proportion of centrally nucleated myofibers, 
which is an index of muscle degeneration and regeneration, was reduced by almost 50% in GA 
treated TA muscle (from 7.5% to 4%, Figure 6a) suggesting a reduction on the pathology-derived 
myofiber turn-over. As the OPMD pathology is characterized both in humans and in the A17 mouse 
model by increased fibrosis and collagen deposition in affected muscles, we stained the FvB and 
A17 muscles for markers of fibrosis (ie Collagen I, III via Sirius red staining, and Collagen VI via 
immunostaining). As expected, saline-treated A17 muscles were more fibrotic than age matched 
saline treated FvB muscles. GA treatment significantly decreased the amounts of collagen proteins 
detected compared to the wild type levels (Figure 6b-c). Overall these data show that GA 
administration is beneficial in OPMD muscles where it improves muscle strength, and reduces 
aggregates formation, cell turn-over and fibrosis with no significant side-effects. 
 
Oral administration of GA increases muscle strength and reduces the amount of nuclear 
aggregates of OPMD mice 
Since the GA-based drug Wytensin has been authorized for oral prescription in tablet form, we 
tested the effect of GA administered orally in OPMD mice. GA was tested in 10-12 week old A17 
mice (n=6) by formulating the drugs in food pellets to provide a final dose of 12 mg/kg of GA per 
week. Groups of A17 and FvB male mice (n=7 and 8 respectively) were also fed with standard 
chow pellets as control. Food was provided ad libitum, weighed and changed twice a week. During 
the experiment, mice fed with GA-supplemented chow ate 15% less food than mice provided with 
standard chow possibly due to the unpleasant taste of the drugs. However, at the end of the 
experiment all mice had gained a similar amount of weight (Supplementary figure 6a-b). As 
performed for the intraperitoneally-delivered drug experiments, we assessed whether GA affects 
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locomotor activity of the mice and again no difference was observed between control groups and 
GA-treated mice for any of the parameters analyzed at the end of the treatment period 
(Supplementary figure 7). Analysis of PABPN1-positive aggregates showed a decrease in both 
the percentage of nuclei containing aggregates and the size of the aggregates in muscles treated 
with GA compared with muscles of control mice (Figure 7a-c). However we did not observe a 
change in the percentage of centrally nucleated fibers (data not shown). As for the experiment 
based on i.p. administration, no change was observed in the muscle weight of TA, EDL, Sol and 
Gast at the end of the study (data not shown). Forelimb strength showed a strong trend towards 
an improvement in A17 mice treated with GA compared with control mice (unpaired t-test: 
*p=0.038) and was essentially normalized to the level of WT FvB mice (Figure 7d). Overall these 
results indicate that GA provided orally is also effective in A17 mice by increasing the muscle 
strength and significantly reducing the size and number of aggregates. 
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Discussion  
OPMD is a late onset disease associated with the formation of intracellular aggregates forming 
nuclear inclusions in affected tissues, similar to what is found in other adult neurological 
proteinopathies like Huntington's, Parkinson's, Alzheimer’s disease, frontotemporal dementia, 
spinocerebellar ataxias, inclusion body myositis, spinal and bulbar muscular atrophy, myotonic 
dystrophy and prion diseases like Creutzfeldt-Jakob (50–52). At present, the contribution of 
PABPN1 aggregates to the OPMD phenotype is still a subject of debate, but it is commonly 
accepted that aggregates, the aggregation process and/or the early oligomeric species of 
expPABPN1 are toxic and crucially involved in the OPMD pathology (2). The development of 
pharmacological molecules targeting these nuclear aggregates may therefore provide a valid 
approach for the treatment of OPMD. Several drugs have demonstrated positive effects in 
preclinical models of OPMD, such as 6-aminophenanthridine (6AP) and GA in Drosophila (24), 
and doxycyclin (25), cystamine (27) and trehalose in mice, with the latter progressed to clinical 
trial stages in OPMD patients (NCT02015481 on clinicaltrial.gov).  
In this study, we tested the effect of GA in a cellular model of OPMD and its therapeutic 
potential in a relevant mouse model of the disease. First of all, we showed that GA decreases the 
percentage and size of nuclear aggregates both in vitro and in vivo. GA and 6AP have previously 
been shown to reduce the size of aggregates and improve the pathology in a Drosophila model of 
OPMD (24). However, while 6AP was shown to use the ribosome-borne protein folding activity 
of the large ribosomal RNA (PFAR) mechanism to reduce the size of aggregates, the mechanism 
of action of GA has not been addressed. Here the results are consistent with a model where GA 
promotes UPR in models of OPMD by acting through the UPR pathway initiated by PERK. In 
response to GA supplementation, we observed both an increase in phosphorylation of eiF2α and 
an increase in Xbp1 splicing. It has been described that Xbp1 splicing is regulated by activation of 
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both PERK (through increased expression of Atf4 that is known to enhance Xbp1 splicing (54)) 
and IRE1α pathways. A cross-talk between PERK and IRE1α has been previously demonstrated 
for miR-30c-2-3p expression that is activated by PERK/NF-κB and inhibits the IRE1-dependant 
transcription factor Xbp1 (55, 56). Here, instead, we show that GA supplementation in vitro 
increases expression of Atf4 (mediated by PERK pathway) that is known to enhance Xbp1 splicing 
(54).  
It has been shown that GA on its own is not able to modulate UPR related genes in 
unstressed cells (37). We found that cells expressing expPABPN1 did not show a different 
expression of the markers we studied to assess UPR activation compared to control cells. However, 
Ala17 cells clearly responded to the treatment with GA by upregulating such markers, suggesting 
that pre-existing ER stress is present in OPMD cells and that this allows a response to GA treatment. 
A possible explanation for the lack of detection of these UPR signatures in untreated Ala17 cells 
is that the expression of expPABPN1 in OPMD myotubes is not long enough to allow detection of 
UPR response. This is further supported by the observation that in the A17 OPMD mouse model, 
where expPABPN1 is expressed for a longer time, UPR activation is readily detectable.  
Although our study strongly suggests a connection, the link between PABPN1 aggregates 
and ER stress in OPMD remains undefined. OPMD is characterized by mitochondrial, ubiquitin 
proteasome system (UPS) and apoptosis defects (26, 49, 57, 58), all of which can potentially 
generate ER stress. Furthermore, protein misfolding in the ER, nutrient deprivation, oxidative 
stress, calcium disturbance, shortage of chaperone proteins and ageing can also trigger ER stress 
(Integrated stress response, ISR) (59–63) and all these features are likely present in OPMD cells. 
For example it is possible that unresolved ER stress generates more substrates for the UPS that 
would consequently lead to the overwhelming and saturation of the UPS degradation machinery in 
a self-reinforcing pathological cycle (64). Alternatively trapping protein chaperones like HSP70 in 
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the aggregates (65, 66) would make them less available for normal cellular functions, which could 
lead to ER stress.  
Recently, it has been demonstrated that PABPN1 protein regulates nuclear structure and 
homeostasis of Ca2+ (67). The ER is an essential intracellular organelle for many cell functions 
including the maintenance of Ca2+ homeostasis. Calcium is one of the key regulators of cell survival 
and can induce ER stress-mediated apoptosis (68, 69) mainly through mitochondrial cell death (70). 
It has been shown that PABPN1 mutation in OPMD gives rise to multiple Ca2+ defects such as 
alterations of the sarcoplasmic reticulum (SR) Ca2+ content, inhibition of the voltage-gated SR 
calcium release and reduced expression of ryanodine receptor (67). Moreover, the presence of 
TNNT3 pre-mRNA in nuclear aggregates (42) is associated with aberrant calcium sensitivity in 
muscle fibers. These studies show that disturbance of Ca2+ homeostasis plays a role in OPMD 
physiopathology and suggests that this could be one of the major causes of ER stress in OPMD. 
Furthermore OPMD has been proposed as a premature-ageing disease (17) and ER stress is prone 
to be activated in aging since age-related changes such as increased oxidative stress, protein 
misfolding, impairment of calcium homeostasis and disturbance of protein synthesis are observed 
when the protein quality is altered (71). Similarly, the enrichment analysis of transcriptomic data 
from the OPMD mouse revealed ER as one of the top-five deregulated cellular components. 
Following the positive effect of GA described in the Drosophila model of OPMD, this study 
is the first demonstration of the effectiveness of GA in a mammalian model of OPMD. Here, we 
decided to dose the mice with 12 mg/kg/week as this translates, after conversion for the body 
surface area, to approximately 10 mg/day in a 70 kg human being which is in the mid-range for the 
administration of Wytensin, a recently discontinued anti-hypertensive drug whose active ingredient 
is GA (47). GA i.p. treatment efficiently reduced the percentage of nuclei containing aggregates 
while simultaneously decreasing muscle fibrosis and improving muscle strength. Furthermore, by 
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providing the drug via oral feeding, we demonstrated that the drug was still active and able to 
decrease the percentage of aggregates using the oral route of delivery, which is compatible with 
clinical application in humans.  
A direct comparison with trehalose, the only anti-aggregate therapeutic strategy that has yet 
progressed to clinical application for OPMD, is impossible due to the different doses, route of 
delivery and outcome measures used to study these compounds. However, the efficacy on reducing 
the amount of aggregates and the functional muscle improvement seem to be at least comparable 
if not substantially better after administration of GA, and with the further advantage that GA is 
already a well-characterized drug that entered the market although for a different pathological 
condition. This drug (ie Wytensin) was discontinued mainly due to some side-effects (e.g. dizziness 
and lethargy) that we also observed in the current study soon after dosing the mice. However, our 
study demonstrates that the chronic administration with GA, at least at the doses used, does not 
affect the locomotor activity in the long term. In conclusion, we suggest that GA ameliorates 
OPMD acting, at least partially, by finely modulating the ER stress response and reducing the 
aggregate formation. GA and novel GA derivatives thus have significant therapeutic potential for 
translation into clinical trials for the treatment of OPMD. 
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Materials and Methods 
 
Drug preparation 
For in vitro experiments, Guanabenz acetate (GA) (G-110, Sigma) was prepared in DMSO at a 
stock concentration of 100 mM. Fresh aliquots were used for each new experiment at concentration 
ranging from 0.1 to 20 μM. For the intraperitoneus (IP) injection, GA was first prepared in 5% 
DMSO and then diluted to the final concentration at 4 mg/kg of bodyweight with saline (NaCl 
0.9% in water). For the oral feeding experiments, food supplemented with GA was prepared using 
the 2016.12 based diet provided by Envigo.  
 
Cell culture 
Primary immortalized mouse myoblasts H2KB IM2 (control cells) are derived from conditionally 
immortalized mice using a temperature-sensitive SV40 large T-antigen (tsA58) transgene (72). 
Mutated PABPN1 (Ala17) and wild-type PABPN1 (Ala10) stable cell lines have been established 
from IM2 cells transfected with a plasmid containing either mutated or wild type PABPN1 under 
a desmin promoter driving myotube-specific expression (43). Cells were cultivated on matrigel 
coated surface in DMEM supplemented with 20% of fœtal calf serum (Invitrogen), 0.5% of chick 
embryo extract (Seralab), 100 U/ml penicillin-streptomycin antibiotic (Thermofisher) and 10 U/ml 
interferon-gamma (Millipore) at 33°C in a humidified 5% CO2 air atmosphere. For Ala10 and 
Ala17 cell lines containing a resistance gene, 500 µg/ml de geneticin (G418; Life Technologies) 
was added to the media. At 90% of confluency, cells were differentiated in DMEM supplemented 
with 10% horse serum and 1% penicillin-streptomycin at 37°C in a 5% CO2 humidified atmosphere.  
 
PABPN1 immunostaining in cells: 
19 
 
For immunostaining, H2KB cells were cultivated in Ibidi 35 mm Dishes (Biovalley). 
Immunostaining of PABPN1 was performed at 5 days of differentiation. Cells were washed once 
in PBS and fixed for 10 min with paraformaldehyde-PBS. Cells were then incubated for 15 min in 
PBS-glycine 0.1 M and permeabilized in blocking buffer containing 3% BSA, 5% goat serum in 
0.2% PBS-Triton X-100. Anti-PABPN1 primary antibody (1/200; ab75855 Abcam) was incubated 
1 hour at room temperature in blocking buffer. Cells were washed three times with 0.1% PBS-
Triton X-100 prior to incubation with goat anti rabbit secondary antibody conjugated to Alexa 
Fluor 488 (Life Technologies) together with Phalloidin 555 (Interchim).  
 
Western blot 
Proteins were extracted by sonicating the cells in RIPA buffer (0.15 M NaCl, 0.1% SDS, 50 mM 
Tris-HCl (pH 8), 2 mM EDTA and 10% Triton-X-100 with protease inhibitor cocktail (Complete, 
Roche Diagnostics) and phosphatase inhibitor cocktail (Santa Cruz; sc-45064)). Protein 
concentration was determined by colorimetric detection method (Pierce BCA Protein Assay; 
Thermo Fisher). Proteins were separated on 4–12% Bis–Tris gels (Invitrogen) and transferred onto 
a PVDF membrane for 1 h at constant 250 mA at 4°C. Membranes were blocked by incubation in 
5% fat free milk or BSA in 1X TBS, 0.1% Tween-20 (TBST) for 1h at room temperature under 
agitation. Membranes were stained with primary antibodies (PABPN1 Abcam ab75855; eiF2α-P 
Cell signaling #9721; eiF2α total Cell signaling #9722) overnight at 4°C under agitation. The next 
day, membranes were washed in TBST and incubated with appropriate secondary antibodies. The 
G:Box system (Syngene) was used to detect the signals from the membranes. 
 
RT-PCR and Real-time qRT-PCR 
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Total RNA was extracted from cell and skeletal muscle samples using Trizol reagent (Invitrogen) 
according to the manufacturer’s instructions. RNA quality and purity was determined using a ND-
1000 NanoDrop spectrophotometer (NanoDrop Technologies). RNA (100 ng for human muscle 
biopsies, 1 µg for cell pellets and mouse muscle biopsies) was reverse transcribed using M-MLV 
reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. The splicing of 
Xbp1 mRNA was monitored by PCR with 0.5-1 µl of cDNA using Reddy mix polymerase (Thermo 
Scientific) according to the manufacturer’s instructions. Primers sparing the 26 bp intron sequences 
are listed in Table S1. The reaction mixture was heated to 94°C for 5 min and followed by 35 PCR 
cycles: 30 s at 94°C, 30 s at 55°C and 30 s at 72°C followed by a last elongation step at 72°C for 7 
min. PCR products from unspliced and alternatively spliced Xbp1 mRNAs, which are 172 and 146 
bp, respectively, were resolved on 5% non-denaturing polyacrylamide or 2% agarose ethydium 
bromide stained gels. cDNA was used for quantitative PCR reaction using SYBR green mix buffer 
(LightCycler 480 Sybr green I Master) in a total reaction volume of 9 µl. The PCR reaction was 
carried out as follows: 8 min at 95◦C followed by 50 cycles of the following: 15 s at 95°C, 15 s at 
60°C and 15 s at 72°C. Specificity of the PCR products was checked by melting curve analysis 
using the following program: 65°C increasing by 0.11°C/s to 97°C. The expression level of each 
mRNA was normalized to that of human B2M mRNA (beta-2 microglobulin) or murine Rpl0 
mRNA (large ribosomal protein, subunit P0) expression. Expression levels were calculated 
according to the ΔΔCt method. The sequences of primers used for RT-PCR and for real-time qRT-
PCR are listed in Table S1. 
 
Mice 
A17 transgenic mice have been previously described (25, 49). Male A17 and wild-type FvB (WT) 
controls were generated by crossing the heterozygous carrier strain A17 with FvB mice. The mice 
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were genotyped by PCR about four weeks after birth. Animals were housed with food and water 
ad libitum in minimal disease facilities (Royal Holloway, University of London).  
 
Drug administration 
For the systemic treatment of OPMD a total of 12 mg/kg/week of GA was administered using either 
food chow or intraperitoneal injections. The total amount of GA administered per week is in the 
range of the dose of the GA based Wytensin used in human (tested in clinical trial from ~0.23 to 
3.7 mg/kg/week; (73)) for the dose conversion human/mouse see FDA guidance for industry, 2005, 
Center for Drug Evaluation and Research (CDER), July 2005. For the oral feeding experiment, a 
2-week long pilot experiment in FvB healthy mice was conducted to measure the amount of food 
needed for 13 weeks. The calculation resulted on mice eating an average of 2 pellets (2.8 grams 
each) per day. For the experiment in OPMD mice, 10-12 week old mice per group (mice fed with 
GA or bare food) were caged individually and bare or the GA-supplemented pellets (GA was 
10mg/kg correspondent to 0.028mg GA/pellet) changed twice a week for 13 weeks until the end 
of the experiment. During the experiment, food was weighted each time in order to assess the 
amount of food eaten by the mice. For the intraperitoneal injection, GA was bought from Sigma 
and diluted in 5% DMSO in saline. Groups of 10-12 week old A17 or FvB mice were injected with 
either GA 4 mg/kg/injection or with 5% DMSO in saline three times per week for 13 weeks.  
 
Assessment of functional readouts in living mice 
Mouse open-field behavioral activity  
Soon after the first i.p. injection of GA or saline, activity of mice was evaluated for 60 minutes (12 
bins of 5 minutes each) using open field behavioral monitoring (Table S2) and data obtained per 
each mouse were averaged. Activity cages from Linton Instruments were used and data were 
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collected using Amonlite software (vs 1.4). During the last 2 weeks of treatment with either oral 
feeding or intraperitoneal injections, the same cages were used to monitor the activity of treated 
mice according to a protocol designed following the TREAT-NMD guidelines (TREAT-NMD 
SOP: DMD_M.2.1.002). Briefly, mice were acclimatized to the test chamber for 60 min every day 
for 4 consecutive days. On the days of data collection, mice were acclimatized for 30 min before 
data acquisition and data were then acquired every 5 minutes for 1h. This protocol was repeated 
for 4 days and data obtained per each mouse were averaged. As described in Results, only the first 
30 minutes of analyses were considered indicative of the locomotor behavior.  
 
Grip strength test 
The forelimb strength of mice treated with either oral feeding or i.p. injections was assessed using 
a commercial grip strength monitor (Linton Instrumentation, Norfolk, UK). The protocol described 
in the TREAT-NMD guidelines was used for the oral feeding experiment (5 tests per mouse over 
a 3-day period, TREAT-NMD SOP: DMD_M.2.2.001). Mice, held from the tail, were allowed to 
grab a metal mesh attached to a force transducer and the force produced after a gentle pull, was 
recorded. 30 seconds were left between each of 5 sequential tests per mouse per day. Data were 
expressed as gram force per gram of the initial body weight. While behavior of the mice orally fed 
with drugs was normal and similar along the 3-days long procedure, we observed that all mice 
treated with chronic i.p. injections (and then manipulated thrice/week by the operator) voluntarily 
did not grab the mesh and preferred to be dragged during both the second and the third days of 
analyses, so only the measurements obtained from the 1st day of analysis were used for the study.  
 
In situ muscle physiology  
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TA muscle strength was measured by in situ muscle physiology performed under terminal 
anesthesia using a protocol already reported in (74). Briefly 24h after the last injection of saline or 
GA, muscle function was assessed using tibialis anterior muscles of each mouse. Mice were deeply 
anesthetized and were carefully monitored throughout the experiment. The distal tendon of the TA 
muscle was dissected and tied with 4.0 braided surgical silk (Interfocus, Cambridge, UK). The 
sciatic nerve was exposed and superfluous branches axotomized. The TA tendon was fixed to the 
lever arm of a 305B dual-mode servomotor transducer (Aurora Scientific, Aurora, Ontario, 
Canada) via a custom made steel s-hook. Bipolar platinum electrodes located in the distal part of 
common peroneal nerve, were used to stimulate using supramaximal square-wave pulses of 0.02 
ms (701A stimulator; Aurora Scientific) TA muscles. Data acquisition and control of the 
servomotors were conducted using a Lab-View-based DMC program (Dynamic muscle control 
and Data Acquisition; Aurora Scientific). Maximum isometric tetanic force (Po) was determined 
from the plateau of the force–frequency relationship following a series of stimulations at 10, 30, 
40, 50, 80, 100, 120, 150 and 180 Hz. Muscle length was measured using digital calipers based on 
well-defined anatomical landmarks near the knee and the ankle. The specific force (N/cm2) was 
calculated by dividing Po by TA muscle cross-sectional area. Overall cross sectional area was 
estimated using the following formula: muscle weight (g)/[TA fiber length (Lf; cm) × 0.6 × 1.06 
(g/cm3)].  
 
Samples harvesting, processing and storing 
Animals were all culled at the end of the study and after the functional analyses. Tibialis anterior 
(TA), extensor digitorum longus (EDL), soleus (SOL) and gastrocnemius (GAST) muscles were 
harvested from mice treated with i.p injections and TA, EDL and SOL muscles were collected from 
mice treated with oral feeding. Muscles from a leg were snap-frozen in liquid nitrogen for WB and 
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RNA studies and the muscles of the contralateral leg were mounted in corks using OCT and frozen 
in pre-chilled isopentane in liquid nitrogen for histological analyses. All samples were stored at -
80°C before analysis. 
 
Immunostaining and histological analyses 
A Bright OTF 5000 cryostat (Bright Instruments, Huntingdon, UK) was used to section muscles at 
10 μm thickness. Muscle sections, placed on coated glass slides (VWR, Lutterworth, UK) were 
stored at -80°C prior to use. Immunohistochemical staining was performed using the following 
antibodies: anti-PABPN1 (rabbit monoclonal, diluted 1:100, Abcam ab75855, ON, 4°C), anti-
Laminin (rat monoclonal; diluted 1:800; Sigma-Aldrich, 1 h RT), anti-Collagen VI (rabbit 
monoclonal; diluted 1:400; Abcam ab182744). Alexa fluor (Molecular Probes) antibodies 
conjugated to 488 or 594 fluorochromes were used to detect the primary antibodies. A published 
protocol (18, 25, 49) was used to counterstain the sarcolemma with Laminin for PABPN1 
immunostaining. Briefly, after fixing sections in Paraformaldeyde 4% the slides were incubated 
with KCl buffer (1 M KCl, 30 mM HEPES, 65 mM PIPES, 10 mM EDTA, 2 mM MgCl2, pH 6.9) 
for 1 h at room temperature. Muscle sections were then blocked with 1% normal goat serum in 0.1 
M PBS, 0.1% Triton X100 for 1 h and then incubated overnight at 4°C with both PABPN1 and 
Laminin primary antibodies diluted in the same buffer. Slides were then washed with 0.1% tween 
20 in PBS and incubated with fluorophore-conjugated secondary antibodies. Slides were mounted 
with mounting medium Vector containing 4’,6-diamidino-2-phenylindole (DAPI, 3 μg/ml; Sigma-
Aldrich Ltd.) to detect nuclei. For Collagen VI staining 5% milk in PBST was used to block for 1h 
at RT the unspecific binding and both the primary and secondary antibodies were incubated for 1h 
at RT in 2.5% fat free milk in PBST. Five, 20X magnification images were randomly taken from 
a blinded observer and used to calculate the percentage of aggregates, the percentage of centrally 
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nucleated fibers and the area covered by collagen VI. A standard protocol for Sirius red was used 
to detect the collagen I and III in TA muscles. Two to three 10X magnification images were 
randomly taken from a blinded observer and used to calculate the area stained by Sirius red and 
expressed as % on the total area. NIH imageJ analysis software was used to analyze the largest 
section of each muscle. 
 
Image acquisition and analysis 
Images were visualized using an Olympus BX60 microscope (Olympus Optical, Hamburg, 
Germany), digitalized using a CCD camera (Photometrics CoolSNAP fx; Roper Scientific) and 
analyzed using MetaView image analysis system (Universal Imaging, Downington, PA), 
MetaMorph imaging system (Roper Scientific, Tucson, AZ, USA) software, and ImageJ 1.44o 
(http://imagej.nih.gov/ij) for quantification analysis. 
 
Electron microscopy 
TA muscles were dissected, cut into small pieces and immediately fixed in 2% glutaraldehyde, 2% 
paraformaldehyde, 0.1M phosphate buffer. After abundant washes and 2% OsO4 post-fixation 
samples were dehydrated at 4°C in graded acetone including a 1% uranyl acetate in 70° acetone 
step and were finally embedded in Epon resin. Thin (70nm) sections were stained with uranyl 
acetate and lead citrate, observed using a Philips CM120 electron microscope (Philips Electronics 
NV) and photographed with a digital SIS Morada camera. 
 
Gene profile analysis 
Enrichment analysis have been performed on the 1099 differentially expressed genes (DEGs) from 
quadriceps muscles of 26-weeks old A17 male mice (n=6 per group) previously deposited on GEO 
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(GSE26604) (see full description of the gene expression analysis in (49). Briefly, total RNA 
extracted from muscles was hybridized to Illumina Mouse v1.1 Bead arrays). This has been done 
using overexpressed test (75) of clusterProfiler package (76) and genome wide annotation for 
Mouse (77) in R. The Benjamini & Hochberg correction method has been applied and results with 
a False Discovery Rate (FDR) lower than 5% and an absolute logFC higher than 0.6 have been 
kept. 
 
Statistical Analysis 
All data are mean values ± standard error of the mean. Statistical analyses were performed using 
the Student t-test and the one-way ANOVA with the Bonferroni post-hoc analysis as indicated. 
GraphPad Prism (version 4.0b; GraphPad Software, San Diego California, USA) was used for the 
analyses. A difference was considered to be significant at *P < 0.05, **P< 0.01 or ***P < 0.001. 
 
Study approval 
Ethical and operational permission for in vivo experiments was granted by the RHUL Animal 
Welfare Committee and the UK Home Office, and this work was conducted under statutory Home 
Office regulatory, ethics, and licensing procedures, under the Animals (Scientific Procedures) Act 
1986 (Project Licence 70/8271).  
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Figures and legends 
 
 
Figure 1: GA treatment reduces PABPN1 aggregates in Ala17 differentiated cells.  
(A-B) Representative immunostaining of PABPN1 aggregates (green) in differentiated Ala17 cells. 
In (A) nuclei are counterstained with Hoechst (blue) and myotubes are visualized using phalloidin 
staining (red). Scale bar = 40 µm in (A). Scale bar = 25 µm in (B). (C) The amount of PABPN1 
aggregates was reduced upon GA treatment. Unpaired t-test, * p<0.05 n = 3 experiments with at 
least 100 nuclei counted per experiment. (D) The size of PABPN1 aggregates is decreased by GA 
treatment. Cumulative rank plots show the size of nuclear aggregates in A17 GA-treated group 
compared to A17 untreated group. Kolmogorov-Smirnov test with *p<0.05. NT= cells treated with 
DMSO only; GA: cells treated with 10 µM GA. 
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Figure 2: Both PERK-P-eiF2α and IRE1-Xbp1 pathways are activated in response to GA 
treatment in OPMD cells. (A) Western blot showing phosphorylated eiF2α (P-eiF2α) in control 
and OPMD cells treated with 10 µM GA for 72h (Ala17 GA) compared to DMSO-treated cells 
(Ala17). No increase in phosphorylation of eiF2α is observed in control cells treated with GA (Ctrl 
GA). (B) P-eiF2α normalized to total eiF2α. One-way ANOVA test with Bonferroni post-hoc test, 
***p <0,001. (C) Downstream key UPR markers are overexpressed in Ala17 cells treated with 10 
µM GA (dark grey) while unchanged in control cells (light grey). mRNA levels were normalized 
to RPLP0 mRNA level (P0). n=3 per group. One-way ANOVA test *p<0.05, ***p<0.001, ****p< 
0.0001 ns: not significant (n=3). (D) 10 µM GA treatment activates Xbp1 alternative splicing in 
Ala17 cells but not in control cells, visualized using RT-PCR. The level of total Xbp1 is comparable 
in Ala17 cells and in control cells. Xbp1-u: unspliced form; Xbp1-s: spliced form of Xbp1. 
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Figure 3: ER stress in the OPMD mouse model. (A) Electron micrograph of abnormally enlarged 
sarcoplasmic reticulum (SR) in A17 mouse (bottom) as compared to WT mouse (top panel). 
Arrows indicate T-tubules. Scale bar = 2 µm. The boxed area in each left panel is enlarged in the 
right panel. Scale bar = 500 nm. (B) Scatter plot of Cellular component ontology on 1099 
differentially expressed genes (DEGs) from quadriceps muscles of 26-weeks old A17 male mice 
(n=6 per group) previously deposited on GEO (GSE26604). The top 30 cellular components are 
shown in the bubble chart. Gene ratio is shown on the x-axis, point size shows the gene counts and 
point color shows the adjusted p-value. (C) Key UPR downstream genes Grp78, Grp94, Ddit3, 
Dnajc3 and Atf4 are upregulated in A17 mice compared to control mice. 25 week old mice (n=6 
per group) were used for this study. Only Xbp1 splicing profile did not show any change between 
WT and A17 mice. Xbp1-u: unspliced form; Xbp1-s: spliced form of Xbp1 (n=3 mice per group). 
Unpaired t-test **p<0.01, ***p<0.001, ****p< 0.0001. 
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Figure 4: in vivo administration of GA improves the functionality of treated muscles. Top panel: 
scheme with drug administration regimens and behavior test performed. (A) Grip-strength analysis 
performed in mice at the end of the 13-week long treatment shows that forelimbs of mice treated 
with GA are significantly stronger than those of mice treated with saline. Unpaired t-test, *p<0.05. 
(B) in situ muscle physiology in muscles: force-frequency analysis of maximal force generated by 
TA muscles of treated mice shows that GA administration significantly increases the maximal force 
generated by TA muscles. * and # are used to show statistical difference between A17 mice and 
FvB or GA treated mice respectively. One-way Anova test with Bonferroni post-doc test, *p<0.05, 
***p<0.001, #p<0.05. (C) Normalization of maximal force by muscle cross sectional area provides 
a measure of the muscle strength per unit of skeletal muscle called specific maximal force. * and # 
are used to show statistical difference between A17 mice and FvB or GA treated mice respectively. 
One-way ANOVA test with Bonferroni post-doc test, *p<0.05, **p<0.01, ##p<0.01, #p<0.05. (D) 
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Specific maximal force of muscles treated with GA was normalized to the level of control wild 
type muscles (150 hz stimulation is shown). Mean ± s.e.m., n=6; One-way ANOVA test with 
Bonferroni post-doc test, *p<0.05, **p<0.01, ns: not significant. Red and blue stars refer to A17 
GA vs A17 saline or FvB saline vs A17 saline comparisons respectively. 
 
Figure 5: Intraperitoneal injection of GA reduces the amount and the size of aggregates. After 
thirteen weeks of treatment by i.p injection of GA, TA muscles of treated mice were collected and 
PABPN1 expression was analyzed. (A) Detection of PABPN1 intranuclear aggregates (green) and 
laminin (red) by immunofluorescence in sections of treated muscles. Sections were pre-treated with 
1 M KCl to discard soluble PABPN1 from the tissue. Nuclei are counterstained with DAPI (blue). 
Scale bar = 200 µm. (B) Quantification of nuclei containing aggregates in muscle sections indicates 
that treatment with GA significantly reduces the amount of aggregates to ~20% compared to A17 
untreated mice (~35% nuclei containing aggregates). One-way ANOVA test with Bonferroni post-
hoc test ***p<0.001. (C) GA administration reduces the size of intranuclear aggregates. 
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Cumulative rank plots show the size of aggregates in A17 GA-treated group compared to A17 
untreated group. Kolmogorov-Smirnov test with ** p<0.01. (D) Western blot for PABPN1 
expression shows that GA treatment does not change the level of PABPN1. (E) Densitometric 
analysis of western blot for PABPN1 detection shows no difference in PABPN1 expression in 
saline and GA-treated A17 mice normalized to the relative tubulin expression. n=6 in each group. 
Data are presented as mean ± s.e.m. One-way ANOVA test with Bonferroni post-hoc test 
***p<0.001, ns, not significant. 
 
Figure 6: GA administration reduces the percentage of centrally nucleated fibers and the fibrosis 
in muscle. (A) Representative images of histological stainings for Laminin and DAPI were used 
to quantify the percentage of myofibers with central nuclei. GA treatment significantly reduces the 
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percentage of centrally nucleated fibers (CN) compared to saline treated A17 mice (right panel). 
One-way ANOVA test with Bonferroni post-hoc test **p<0.01, ***p<0.001. (B) Representative 
images of the Sirius red staining used to quantify the area covered by Collagen I and III in TA 
muscles of treated mice. Muscle of mice treated with GA have significantly less Collagen I and III 
positive area (Sirius red staining) compared to muscles of mice treated with saline (right panel). 
One-way ANOVA test with Bonferroni post-hoc test, ***p<0.001, ns, not significant. (C) 
Representative pictures of Collagen VI immunostaining used to quantify the collagen VI positive 
(+ve) area. Collagen VI +ve area is smaller in GA-treated muscles compared to saline-treated 
muscles (right panel) One-way ANOVA test with Bonferroni post-hoc test **p<0.01, ***p<0.001, 
ns, not significant. Scale bar = 200 µm. n=6 in each group. Data are presented as mean ± s.e.m.   
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Figure 7. GA formulated in food has beneficial effects in forelimb strength and reduces the 
amount and the size of intranuclear aggregates. (A) Detection of PABPN1 nuclear aggregates 
(green) and laminin (red) by immunofluorescence in sections of treated muscles. Sections were 
pre-treated with 1 M KCl to discard all soluble PABPN1 from the tissue. Nuclei are counterstained 
with DAPI (blue). Scale bar = 200 µm. (B) Percentage of nuclei containing aggregates in muscle 
sections indicates that the treatment with GA significantly reduces the amount of aggregates to 
~20% compared to A17 untreated mice. One-way ANOVA test with Bonferroni post-hoc test 
***p<0.001 (C) GA administration reduces the size of intranuclear aggregates. n=6 per group. 
Cumulative rank plots show the size of aggregates in A17 GA-treated group compared to A17 
untreated group. Kolmogorov-Smirnov test with ** p<0.01. (D) Forelimb force of A17 mice 
treated with GA showed a trend towards an increase in strength compared to the force of mice 
treated with saline. Unpaired t-test, *p<0.05. ns, not significant. Data are presented as mean ± s.e.m. 
n=6-8 per group.  
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eIF2α: eukaryotic translation initiation factor-2; EDL: extensor digitorum longus; ER: endoplasmic 
reticulum; GA: guanabenz acetate; Gast: gastrocnemius; lncRNA: long non-coding RNA; ns: not 
significant; OPMD: oculopharyngeal muscular dystrophy; PABPN1: poly(A) binding protein 
nuclear 1; PFAR: protein folding activity of the ribosome; sem: standard error of the mean; SR: 
sarcoplasmic reticulum; UPR: unfolded protein response; snoRNA: small nucleolar RNA; Sol: 
soleus; TA: tibialis anterior. 
